NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addict...
Published : 10 Oct 2022
Read MoreFrench Biotech client awarded yet another contract extension to Aagami. Client is a publicly listed company developing a drug for smoking cessation.&n...
Published : 15 Jul 2022
Read MoreWe are glad to announce that Aagami is attending the International Life Sciences Partnering Conference – BIO-Europe® 2022 (October 2...
Published : 11 Jul 2022
Read MoreAagami successfully completed 45+ One-on-One partnering meetings in BIO International Convention 2022 in San Diego (June 13-16).Aagami also represente...
Published : 23 Jun 2022
Read MoreAagami has bagged an assignment to find and establish Partnerships for FDA approved Manufacturing facilities in the US for the controlled substan...
Published : 14 Jun 2022
Read MoreWe have received yet another assignment from a past client who has been giving Aagami periodic assignments after tasting first success with us 5 years...
Published : 16 May 2022
Read MoreAagami has bagged an assignment to supporting Licensing/Investments needs of an Israel based revolutionary solution in IVF implantation. The...
Published : 25 Mar 2022
Read MoreAagami’s French biotech client has further extended its contract with Aagami for a period of 6 months. This is the fourth extension and is a proven ...
Published : 10 Jan 2022
Read MoreAs the year 2021 ended, Aagami got a licensing term sheet signed for its client.Other details are confidential until press release by the client and i...
Published : 31 Dec 2021
Read MoreAagami are proud to announce that their Current Japanese client has given a new assignment, to seek partnerships for their other assets in the pipelin...
Published : 27 Dec 2021
Read More